309 related articles for article (PubMed ID: 21288495)
21. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
[TBL] [Abstract][Full Text] [Related]
22. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation.
Bartelink IH; Bredius RG; Belitser SV; Suttorp MM; Bierings M; Knibbe CA; Egeler M; Lankester AC; Egberts AC; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2009 Feb; 15(2):231-41. PubMed ID: 19167683
[TBL] [Abstract][Full Text] [Related]
23. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Dupuis LL; Sibbald C; Schechter T; Ansari M; Gassas A; Théorêt Y; Kassir N; Champagne MA; Doyle J
Biol Blood Marrow Transplant; 2008 May; 14(5):576-82. PubMed ID: 18410900
[TBL] [Abstract][Full Text] [Related]
24. Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.
Beri R; Chunduri S; Sweiss K; Peace DJ; Mactal-Haaf C; Dobogai LC; Shord S; Quigley JG; Chen YH; Mahmud N; Rondelli D
Bone Marrow Transplant; 2010 Feb; 45(2):249-53. PubMed ID: 19543331
[TBL] [Abstract][Full Text] [Related]
25. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
[TBL] [Abstract][Full Text] [Related]
26. Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.
Tse WT; Duerst R; Schneiderman J; Chaudhury S; Jacobsohn D; Kletzel M
Bone Marrow Transplant; 2009 Aug; 44(3):145-56. PubMed ID: 19182832
[TBL] [Abstract][Full Text] [Related]
27. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.
Fisher VL; Barnes YJ; Nuss SL
Oncol Nurs Forum; 2006 Nov; 33(2):E36-43. PubMed ID: 16518436
[TBL] [Abstract][Full Text] [Related]
28. Thirteen years' experience of pharmacokinetic monitoring and dosing of busulfan: can the strategy be improved?
Buffery PJ; Allen KM; Chin PK; Moore GA; Barclay ML; Begg EJ
Ther Drug Monit; 2014 Feb; 36(1):86-92. PubMed ID: 24299921
[TBL] [Abstract][Full Text] [Related]
29. Dosing algorithm revisit for busulfan following IV infusion.
Wang Y; Kato K; Le Gallo C; Armstrong E; Rock E; Wang X
Cancer Chemother Pharmacol; 2015 Mar; 75(3):505-12. PubMed ID: 25561350
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.
Davis JM; Ivanova A; Chung Y; Shaw JR; Rao KV; Ptachcinski JR; Sharf AA; Serody JS; Armistead PM; Wood WA; Coghill JM; Jamieson KJ; Vincent BG; Riches ML; Shea TC; Alexander MD
Biol Blood Marrow Transplant; 2019 Feb; 25(2):391-397. PubMed ID: 30244102
[TBL] [Abstract][Full Text] [Related]
31. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results.
Michel G; Valteau-Couanet D; Gentet JC; Esperou H; Socié G; Méchinaud F; Doz F; Neven B; Bertrand Y; Galambrun C; Demeocq F; Yakouben K; Bordigoni P; Frappaz D; Nguyen L; Vassal G
Pediatr Blood Cancer; 2012 Jan; 58(1):90-7. PubMed ID: 21254374
[TBL] [Abstract][Full Text] [Related]
32. Retrospective appraisal of busulfan dose adjustment in children.
Dupuis LL; Najdova M; Saunders EF
Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
[TBL] [Abstract][Full Text] [Related]
33. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation.
Jacobson P; Park JJ; DeFor TE; Thrall M; Abel S; Krivit W; Peters C
Bone Marrow Transplant; 2001 Apr; 27(8):855-61. PubMed ID: 11477444
[TBL] [Abstract][Full Text] [Related]
34. Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.
Matthews RH; Emami M; Connaghan DG; Holland HK; Morris LE
Bone Marrow Transplant; 2007 Apr; 39(7):397-400. PubMed ID: 17322933
[TBL] [Abstract][Full Text] [Related]
35. Population pharmacokinetics of busulfan in Saudi pediatric patients undergoing hematopoietic stem cell transplantation.
Alsultan A; Albassam AA; Alturki A; Alsultan A; Essa M; Almuzzaini B; Alfadhel S
Int J Clin Pharm; 2020 Apr; 42(2):703-712. PubMed ID: 32140913
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.
Booth BP; Rahman A; Dagher R; Griebel D; Lennon S; Fuller D; Sahajwalla C; Mehta M; Gobburu JV
J Clin Pharmacol; 2007 Jan; 47(1):101-11. PubMed ID: 17192508
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of inpatient admissions and potential antimicrobial and analgesic dosing errors in overweight children.
Miller JL; Johnson PN; Harrison DL; Hagemann TM
Ann Pharmacother; 2010 Jan; 44(1):35-42. PubMed ID: 20028958
[TBL] [Abstract][Full Text] [Related]
38. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
[TBL] [Abstract][Full Text] [Related]
39. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.
Geddes M; Kangarloo SB; Naveed F; Quinlan D; Chaudhry MA; Stewart D; Savoie ML; Bahlis NJ; Brown C; Storek J; Andersson BS; Russell JA
Biol Blood Marrow Transplant; 2008 Feb; 14(2):220-8. PubMed ID: 18215782
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration.
Trame MN; Bartelink IH; Boos J; Boelens JJ; Hempel G
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1149-55. PubMed ID: 24036908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
